Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 15/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.49 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.49 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.48 |
| ▸ | SRC | P12931 | 8/20 | 0.46 |
| ▸ | ABL1 | P00519 | 5/20 | 0.46 |
| ▸ | PRKDC | P78527 | 4/20 | 0.42 |
| ▸ | EGFR | P00533 | 3/20 | 0.42 |
| ▸ | HCK | P08631 | 3/20 | 0.42 |
| ▸ | KDR | P35968 | 3/20 | 0.42 |
| ▸ | MTOR | P42345 | 3/20 | 0.42 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.42 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16783795 | 0.91 | PIK3CD (0.47) | PIK3CDPIK3CGPIK3R1CSNK1EPIK3CB | |
| SCHEMBL16783794 | 0.91 | PIK3CD (0.47) | PIK3CDPIK3CGPIK3R1CSNK1EPIK3CB | |
| SCHEMBL21337709 | 0.89 | PIK3CD (0.45) | PIK3CDPIK3CGPIK3R1CSNK1EPIK3CB | |
| SCHEMBL16783423 | 0.88 | PIK3CD (0.55) | PIK3CDPIK3CGPIK3R1CSNK1EPIK3CB | |
| SCHEMBL16783385 | 0.88 | PIK3CD (0.48) | PIK3CDPIK3CGPIK3R1CSNK1EPIK3CB | |
| SCHEMBL16783519 | 0.87 | PIK3CD (0.48) | PIK3CDPIK3CGPIK3R1CSNK1EPIK3CB | |
| SCHEMBL16783870 | 0.86 | SRC (0.46) | PIK3CDPIK3CGPIK3R1CSNK1EPIK3CB | |
| SCHEMBL16783869 | 0.86 | SRC (0.46) | PIK3CDPIK3CGPIK3R1CSNK1EPIK3CB | |
| SCHEMBL16783559 | 0.82 | PIK3CD (0.48) | PIK3CDPIK3CGPIK3R1CSNK1EPIK3CB | |
| SCHEMBL16783876 | 0.82 | PIK3CD (0.53) | PIK3CDPIK3CGPIK3R1CSNK1EPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3083617-B1 | ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARM SPA (IT) | 2019-09-11 | — | — | EP | disclosed |
| EP-3083617-B1 | ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARM SPA (IT) | 2019-09-11 | — | — | EP | disclosed |
| EP-3083617-A1 | ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2016-10-26 | — | — | EP | disclosed |
| US-9321776-B2 | Isochromene derivatives as phoshoinositide 3-kinases inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-04-26 | — | — | US | disclosed |
| US-9321776-B2 | Isochromene derivatives as phoshoinositide 3-kinases inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-04-26 | — | — | US | disclosed |
| US-9321776-B2 | Isochromene derivatives as phoshoinositide 3-kinases inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-04-26 | — | — | US | disclosed |
| WO-2015091685-A1 | ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015091685-A1 | ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-06-25 | — | — | WO | disclosed |
| US-20150166549-A1 | ISOCHROMENE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-06-18 | — | — | US | disclosed |
| US-20150166549-A1 | ISOCHROMENE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-06-18 | — | — | US | disclosed |
| US-20150166549-A1 | ISOCHROMENE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166549-A1 | ISOCHROMENE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | PIKFYVE, IP6K2, IP6K3 | PIK3CD 15/4885PIK3CG 23/4885PIK3R1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.